(Total Views: 804)
Posted On: 12/31/2022 2:32:44 PM
Post# of 153903
Since nobody has anything to say, I figure I will post some reading material on NASH. This article may have been posted before. However, this is a good read to help understand the atmosphere of our next clinical. For those of us that have sworn to see this drug to market (sink or swim), it pays to know as much as possible. Good luck to LONGS! I hope you have the greatest year ever!
"Although some amelioration of inflammation has been seen, these drugs did not improve the fibrosis component of NASH. Therefore, dietary modification and weight reduction have remained the cornerstone of treatment of NASH; moreover, they have shown to improve histological activity as well as fibrosis. The search for an ideal drug or ‘Holy Grail’ within this landscape of possible agents continues, as weight reduction is achieved only in less than 10% of patients. In this current review, we summarize the drugs for NASH which are under investigation, and we provide a critical analysis of their up-to-date results and outcomes."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...o=0.602410
"Although some amelioration of inflammation has been seen, these drugs did not improve the fibrosis component of NASH. Therefore, dietary modification and weight reduction have remained the cornerstone of treatment of NASH; moreover, they have shown to improve histological activity as well as fibrosis. The search for an ideal drug or ‘Holy Grail’ within this landscape of possible agents continues, as weight reduction is achieved only in less than 10% of patients. In this current review, we summarize the drugs for NASH which are under investigation, and we provide a critical analysis of their up-to-date results and outcomes."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...o=0.602410
(5)
(0)
